{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Standard+of+Care+Dosing&page=5",
    "query": {
      "intervention": "Standard of Care Dosing",
      "page": 5
    },
    "page_size": 10
  },
  "pagination": {
    "page": 5,
    "page_size": 10,
    "total_count": 543,
    "total_pages": 55,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Standard+of+Care+Dosing&page=6&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Standard+of+Care+Dosing&page=4&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-06T07:43:13.368Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04743804",
      "title": "Ravulizumab in Thrombotic Microangiopathy Associated With a Trigger",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Thrombotic Microangiopathy"
      ],
      "interventions": [
        {
          "name": "Ravulizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Best Supportive Care",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Alexion Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2021-06-29",
      "completion_date": "2022-12-22",
      "has_results": true,
      "last_update_posted_date": "2024-10-01",
      "last_synced_at": "2026-10-06T07:43:13.368Z",
      "location_count": 20,
      "location_summary": "Tucson, Arizona • Orange, California • Washington D.C., District of Columbia + 14 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04743804"
    },
    {
      "nct_id": "NCT04351152",
      "title": "Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Patients With COVID-19",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Coronavirus Disease 2019 (COVID-19) Pneumonia"
      ],
      "interventions": [
        {
          "name": "Lenzilumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Standard of Care",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Humanigen, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 520,
      "start_date": "2020-05-05",
      "completion_date": "2021-03",
      "has_results": false,
      "last_update_posted_date": "2021-03-03",
      "last_synced_at": "2026-10-06T07:43:13.368Z",
      "location_count": 18,
      "location_summary": "Phoenix, Arizona • Irvine, California • Los Angeles, California + 13 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04351152"
    },
    {
      "nct_id": "NCT00142935",
      "title": "Effectiveness of Opiate Replacement Therapy Administered Prior to Release From a Correctional Facility - 1",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "HIV Prevention",
        "Opioid-Related Disorders"
      ],
      "interventions": [
        {
          "name": "Pre-release Initiation of MMT",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Post Release Initiation of MMT.",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Standard of Care Plus",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "The Miriam Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 87,
      "start_date": "2006-09",
      "completion_date": "2009-12",
      "has_results": true,
      "last_update_posted_date": "2014-06-06",
      "last_synced_at": "2026-10-06T07:43:13.368Z",
      "location_count": 1,
      "location_summary": "Providence, Rhode Island",
      "locations": [
        {
          "city": "Providence",
          "state": "Rhode Island"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00142935"
    },
    {
      "nct_id": "NCT04341441",
      "title": "Will Hydroxychloroquine Impede or Prevent COVID-19",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "COVID-19",
        "Coronavirus",
        "Coronavirus Infections",
        "SARS-CoV 2"
      ],
      "interventions": [
        {
          "name": "Hydroxychloroquine - Daily Dosing",
          "type": "DRUG"
        },
        {
          "name": "Hydroxychloroquine - Weekly Dosing",
          "type": "DRUG"
        },
        {
          "name": "Placebo oral tablet",
          "type": "OTHER"
        },
        {
          "name": "Monitoring Visit - Baseline",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Monitoring Visit - Week 4",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Monitoring Visit - Week 8",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Weekly Assessment",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Henry Ford Health System",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 624,
      "start_date": "2020-04-07",
      "completion_date": "2020-12-15",
      "has_results": true,
      "last_update_posted_date": "2022-06-21",
      "last_synced_at": "2026-10-06T07:43:13.368Z",
      "location_count": 1,
      "location_summary": "Detroit, Michigan",
      "locations": [
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04341441"
    },
    {
      "nct_id": "NCT01509911",
      "title": "A Clinical Trial of Anti-Angiogenic Drug Combination Tl-118 for Pancreatic Cancer Patients Who Are Starting Gemcitabine Treatment",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "TL-118",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tiltan Pharma Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 99,
      "start_date": "2012-01",
      "completion_date": "2017-01",
      "has_results": false,
      "last_update_posted_date": "2016-02-05",
      "last_synced_at": "2026-10-06T07:43:13.368Z",
      "location_count": 2,
      "location_summary": "Atlanta, Georgia • White Plains, New York",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "White Plains",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01509911"
    },
    {
      "nct_id": "NCT07746271",
      "title": "Gestational Hypertension and Preeclampsia Blood Pressure (BP) Treatment Goals Less Than 140/90 vs. Less Than 160/110 mmHg: The GOALPOST Trial",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hypertension in Pregnancy",
        "Obstetrical Complications"
      ],
      "interventions": [
        {
          "name": "Anti-hypertensive medication titrated to a BP goal of <140/90 mmHg",
          "type": "DRUG"
        },
        {
          "name": "Usual Care: Anti-hypertensive medication for BP ≥160/110 mmHg titrated to a goal of < 160/110 mmHg",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "The George Washington University Biostatistics Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "14 Years",
        "maximum_age": "56 Years",
        "sex": "FEMALE",
        "summary": "14 Years to 56 Years · Female only"
      },
      "enrollment_count": 4120,
      "start_date": "2026-09-30",
      "completion_date": "2030-04-30",
      "has_results": false,
      "last_update_posted_date": "2026-09-18",
      "last_synced_at": "2026-10-06T07:43:13.368Z",
      "location_count": 14,
      "location_summary": "Birmingham, Alabama • San Francisco, California • Chicago, Illinois + 10 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07746271"
    },
    {
      "nct_id": "NCT02309892",
      "title": "A Dose Escalation Study of L-DOS47 in Recurrent or Metastatic Non-Squamous NSCLC",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "L-DOS47",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Helix BioPharma Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2015-04-20",
      "completion_date": "2019-09-20",
      "has_results": true,
      "last_update_posted_date": "2024-06-03",
      "last_synced_at": "2026-10-06T07:43:13.368Z",
      "location_count": 2,
      "location_summary": "Cleveland, Ohio • Houston, Texas",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02309892"
    },
    {
      "nct_id": "NCT03939065",
      "title": "Sensor Augmented Pump (SAP) Therapy for Inpatient CFRD Management",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cystic Fibrosis-related Diabetes",
        "Cystic Fibrosis Pulmonary Exacerbation",
        "Cystic Fibrosis in Children"
      ],
      "interventions": [
        {
          "name": "Sensor Augmented Pump Therapy",
          "type": "DEVICE"
        },
        {
          "name": "Standard of Care with CGM",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "8 Years to 25 Years"
      },
      "enrollment_count": 1,
      "start_date": "2020-06-12",
      "completion_date": "2022-06-30",
      "has_results": false,
      "last_update_posted_date": "2023-03-22",
      "last_synced_at": "2026-10-06T07:43:13.368Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03939065"
    },
    {
      "nct_id": "NCT02806947",
      "title": "A Study to Evaluate Steroid-free Treatment for Standard-Risk aGVHD (BMT CTN 1501)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute GVHD"
      ],
      "interventions": [
        {
          "name": "Sirolimus",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Medical College of Wisconsin",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 127,
      "start_date": "2016-10",
      "completion_date": "2019-02-19",
      "has_results": true,
      "last_update_posted_date": "2021-11-01",
      "last_synced_at": "2026-10-06T07:43:13.368Z",
      "location_count": 21,
      "location_summary": "Duarte, California • Los Angeles, California • Gainesville, Florida + 16 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02806947"
    },
    {
      "nct_id": "NCT02345356",
      "title": "A Genomic Approach to Warfarin Dose Prescription in Admixed Caribbean Hispanics",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Atrial Fibrillation",
        "Deep Vein Thrombosis",
        "Cardiac Valvular Insufficiency",
        "Coagulopathies",
        "Pulmonary Embolism"
      ],
      "interventions": [
        {
          "name": "Genotype-guided",
          "type": "GENETIC"
        },
        {
          "name": "Standard-of-Care",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "GENETIC",
        "OTHER"
      ],
      "sponsor": "University of Puerto Rico",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "21 Years to 90 Years"
      },
      "enrollment_count": 200,
      "start_date": "2016-01",
      "completion_date": "2022-05-17",
      "has_results": false,
      "last_update_posted_date": "2022-05-19",
      "last_synced_at": "2026-10-06T07:43:13.368Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02345356"
    }
  ]
}